Teijin is a technology-driven global group of companies comprising of more than 170 companies and employing some 20,000 people across 20 countries worldwide.

Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains:

• High-performance materials including aramid, carbon fibers and composites, as well as resin and plastic processing, polyester fibers and products converting
• Healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare
• IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment.

Deeply committed to its stakeholders, as expressed in the brand statement “Human Chemistry, Human Solutions,” Teijin aims to be a company that supports the society of the future.

In accordance with their commitment statement, Teijin launched a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) service – Teijin CDMO, consisting of the two subsidiaries “TEIJIN REGENT CO., LTD.” and “Japan Tissue Engineering. Co., ltd. (J-TEC)”. TEIJIN REGENET and J-TEC specialize in cell therapies including tissue-engineered products, with the aim of supporting the process development and manufacturing of cell and gene therapeutic products in Japan - taking innovative science from concept to patient treatment.

TEIJIN REGENT is established through an incorporation-type company split, with succeeding the rights and obligations arising from its CDMO business from Teijin. Through the license agreement between Teijin and J-TEC executed on April 2023, J-TEC shares their expertise and know-hows with TEIJIN REGENT for enabling to provide well established CDMO services with clients.

J-TEC, a pioneer of regenerative medicine in Japan was acquired by Teijin in March 2021.
J-TEC has been Japan’s leading manufacturer of regenerative medicine products, accomplishing marketing authorization of the following products so far:

• October 2007 –an autologous cultured epidermis, 'JACE' (Japan's first regenerative medical product)
• July 2012 –an autologous cultured cartilage, 'JACC'
• March 2020 –an autologous cultured corneal epithelium, 'NEPIC'
• June 2021 –an autologous cultured oral mucosal epithelium, 'OCURAL'
• March 2023 –an autologous cultured epidermis containing melanocyte, 'JACEMIN'

'JACE', 'JACC', and 'NEPIC' are Japan's first regenerative medical products for use in plastic and reconstructive surgery, orthopaedic surgery, and ophthalmology, respectively. Of the 20 regenerative medical products (including in vivo gene therapy) approved in Japan, 5 are J-TEC products (As of August 1, 2023).